## Marek Widera

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/199694/marek-widera-publications-by-year.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61 2,099 21 45 g-index

78 3,321 8.9 avg, IF L-index

#	Paper	IF	Citations
61	Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates <i>Cell Research</i> , <b>2022</b> ,	24.7	19
60	Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults <i>Nature Microbiology</i> , <b>2022</b> ,	26.6	4
59	Detection and Quantification of SARS-CoV-2 by Real-Time RT-PCR Assay <i>Methods in Molecular Biology</i> , <b>2022</b> , 2452, 75-98	1.4	O
58	Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma <i>Cancer Cell</i> , <b>2022</b> ,	24.3	1
57	Severe impairment of T-cell responses to BNT162b2 immunization in multiple myeloma patients. <i>Blood</i> , <b>2021</b> ,	2.2	3
56	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	8
55	Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252304	3.7	2
54	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 1109-1114	7	26
53	Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 701198	5.7	4
52	Detection of SARS-CoV-2 in raw and treated wastewater in Germany - Suitability for COVID-19 surveillance and potential transmission risks. <i>Science of the Total Environment</i> , <b>2021</b> , 751, 141750	10.2	180
51	Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour. <i>Bioinformatics</i> , <b>2021</b> ,	7.2	4
50	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , <b>2021</b> , 13,	6.2	14
49	Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. <i>Medical Microbiology and Immunology</i> , <b>2021</b> , 210, 235-244	4	9
48	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. <i>Viruses</i> , <b>2021</b> , 13,	6.2	21
47	The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	84
46	Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	40
45	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. <i>Nature</i> , <b>2020</b> , 583, 469-472	50.4	498

## (2018-2020)

44	HIV infection does not alter interferon Areceptor 2 expression on mucosal immune cells. <i>PLoS ONE</i> , <b>2020</b> , 15, e0218905	3.7	2
43	Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples. <i>Journal of Clinical Virology</i> , <b>2020</b> , 127, 104381	14.5	34
42	Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	39
41	Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. <i>Nature</i> , <b>2020</b> , 587, 657-66	2 <sub>50.4</sub>	418
40	A Novel, Broad-Acting Peptide Inhibitor of Double-Stranded DNA Virus Gene Expression and Replication. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 601555	5.7	3
39	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 534731	8.4	6
38	Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. <i>Viruses</i> , <b>2019</b> , 11,	6.2	3
37	Gymnotic Delivery of LNA Mixmers Targeting Viral SREs Induces HIV-1 mRNA Degradation. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	5
36	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. <i>Journal of Clinical Virology</i> , <b>2019</b> , 113, 14-19	14.5	5
35	Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 B2 Homozygous Stem Cells. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 684-687	11.6	26
34	Concurrent administration of IFNII4 and cART in TKO-BLT mice enhances suppression of HIV-1 viremia but does not eliminate the latent reservoir. <i>Scientific Reports</i> , <b>2019</b> , 9, 18089	4.9	3
33	Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2850	8.4	2
32	Clinical Outcome and Viral Genome Variability of Hepatitis B Virus-Induced Acute Liver Failure. <i>Hepatology</i> , <b>2019</b> , 69, 993-1003	11.2	12
31	Behind the scenes of HIV-1 replication: Alternative splicing as the dependency factor on the quiet. <i>Virology</i> , <b>2018</b> , 516, 176-188	3.6	22
30	Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 282-290	19.7	2
29	Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. <i>Journal of Medical Microbiology</i> , <b>2018</b> , 67, 1496-1508	3.2	8
28	Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function. <i>Transplant Infectious Disease</i> , <b>2018</b> , 20, e12817	2.7	11
27	An advanced BLT-humanized mouse model for extended HIV-1 cure studies. <i>Aids</i> , <b>2018</b> , 32, 1-10	3.5	34

26	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. <i>Antiviral Research</i> , <b>2018</b> , 159, 68-76	10.8	8
25	Analysis of Competing HIV-1 Splice Donor Sites Uncovers a Tight Cluster of Splicing Regulatory Elements within Exon 2/2b. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	12
24	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. <i>Journal of Clinical Virology</i> , <b>2017</b> , 93, 46-52	14.5	8
23	HIV-1 persistent viremia is frequently followed by episodes of low-level viremia. <i>Medical Microbiology and Immunology</i> , <b>2017</b> , 206, 203-215	4	8
22	Expression Pattern of Individual IFNA Subtypes in Chronic HIV Infection. <i>Journal of Interferon and Cytokine Research</i> , <b>2017</b> , 37, 541-549	3.5	10
21	Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony-stimulating factor treatment. <i>Hepatology</i> , <b>2016</b> , 64, 1803-1805	11.2	2
20	Balanced splicing at the Tat-specific HIV-1 3 ds A3 is critical for HIV-1 replication. <i>Retrovirology</i> , <b>2015</b> , 12, 29	3.6	24
19	The D-amino acid peptide D3 reduces amyloid fibril boosted HIV-1 infectivity. <i>AIDS Research and Therapy</i> , <b>2014</b> , 11, 1	3	18
18	The PI3K pathway acting on alternative HIV-1 pre-mRNA splicing. <i>Journal of General Virology</i> , <b>2014</b> , 95, 1809-1815	4.9	3
17	Genomic HEXploring allows landscaping of novel potential splicing regulatory elements. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 10681-97	20.1	52
16	A functional conserved intronic G run in HIV-1 intron 3 is critical to counteract APOBEC3G-mediated host restriction. <i>Retrovirology</i> , <b>2014</b> , 11, 72	3.6	16
15	Mutational analysis of the internal membrane proximal domain of the HIV glycoprotein C-terminus. <i>Virology</i> , <b>2013</b> , 440, 31-40	3.6	2
14	HEXploring of the HIV-1 genome allows landscaping of new potential splicing regulatory elements. <i>Retrovirology</i> , <b>2013</b> , 10,	3.6	78
13	A novel assay for detecting virus-specific antibodies triggering activation of Fclreceptors. <i>Journal of Immunological Methods</i> , <b>2013</b> , 387, 21-35	2.5	29
12	An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA. <i>Journal of Virology</i> , <b>2013</b> , 87, 2707-20	6.6	24
11	Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon respor	ise	2
10	Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies		128
9	Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates		2

## LIST OF PUBLICATIONS

8	SARS-CoV-2 infected host cell proteomics reveal potential therapy targets	27
7	Inhibition of papain-like protease PLpro blocks SARS-CoV-2 spread and promotes anti-viral immunity	14
6	SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles	33
5	Optimized qRT-PCR approach for the detection of intra- and extra-cellular SARS-CoV-2 RNAs	6
4	Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings	3
3	Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro	22
2	Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E48	4Q
1	The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype	1